Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study
2012/01/17 by Natalie Spomer, Viviane Klingmann, Ines Stoltenberg +5 · 27 citations
Medicine · Nursing · Pharmacology, Toxicology and Pharmaceutics · #Pharmaceutical studies and practices #Clinical Nutrition and Gastroenterology #Drug Solubulity and Delivery Systems
paper · doi:10.1136/archdischild-2011-300958
Abstract
OBJECTIVE: To explore the acceptance of uncoated drug-free mini-tablets 2 mm in diameter in children aged 0.5-6 years and their ability to swallow the mini-tablets. METHODS: 60 children aged 0.5-6 years (10 subjects per year of life) were enrolled in our prospective, open random, two-way cross-over exploratory pilot study. The children were administered either an uncoated drug-free mini-tablet 2 mm in diameter with a beverage of their choice or 3 ml of glucose syrup 15% followed by the other formulation. Deglutition was visually assessed for the two different dosage forms using a predefined criteria list. RESULTS: The study hypothesis was that children would accept the liquid formulation better than the solid mini-tablets. Surprisingly, the authors found that the acceptance of the mini-tablets, defined as immediate swallowing or chewing first with subsequent swallowing, was higher or at least equal to that of the syrup. Very young children (6-12 months) were fully capable of swallowing the mini-tablets and may even accept them better than the sweet liquid formulation. Some children aged between 2 and 4 years chewed the tablets before swallowing, but still accepted them quite well. The acceptance rate of the mini-tablets in the different age groups was much higher than expected. CONCLUSIONS: Uncoated mini-tablets seem to be a very promising alternative to liquid formulations and could be used at an earlier age in paediatric drug therapy than previously anticipated.
Cited by
- Educational Paper: Formulation-related issues in pediatric clinical pharmacology
- Pediatric-friendly chocolate-based dosage forms for the oral administration of both hydrophilic and lipophilic drugs fabricated with extrusion-based 3D printing
- A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. [europepmc]
- Solid oral forms availability in children: a cost saving investigation. [europepmc]
- Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use. [europepmc]
- Influence of Experimental Conditions on Electronic Tongue Results-Case of Valsartan Minitablets Dissolution. [europepmc]
- Content uniformity of quartered hydrocortisone tablets in comparison with mini-tablets for paediatric dosing. [europepmc]
- Acceptability of placebo multiparticulate formulations in children and adults. [europepmc]
- Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings. [europepmc]
- Dosage form preference consultation study in children and young adults: paving the way for patient-centred and patient-informed dosage form development. [europepmc]
- Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. [europepmc]
- How to Modify Drug Release in Paediatric Dosage Forms? Novel Technologies and Modern Approaches with Regard to Children's Population. [europepmc]
- Acceptability, adherence, and clinical outcomes, of amoxicillin dispersible tablets versus oral suspension in treatment of children aged 2-59 Months with pneumonia, Kenya: A cluster randomized controlled trial. [europepmc]
- Utilization of Ethylcellulose Microparticles with Rupatadine Fumarate in Designing Orodispersible Minitablets with Taste Masking Effect. [europepmc]
- Medicines Acceptability in Hospitalized Children: An Ongoing Need for Age-Appropriate Formulations. [europepmc]
- Digital Light Processing (DLP) 3D Printing of Atomoxetine Hydrochloride Tablets Using Photoreactive Suspensions. [europepmc]
- Development and Evaluation of Feline Tailored Amlodipine Besylate Mini-Tablets Using L-lysine as a Candidate Flavouring Agent. [europepmc]
- Development and content validation of the Pediatric Oral Medicines Acceptability Questionnaires (P-OMAQ): patient-reported and caregiver-reported outcome measures. [europepmc]
- 3D Printing of Mini Tablets for Pediatric Use. [europepmc]
- Children's Preferences for Oral Dosage Forms and Their Involvement in Formulation Research via EPTRI (European Paediatric Translational Research Infrastructure). [europepmc]
- Dosage Forms Suitability in Pediatrics: Acceptability of Analgesics and Antipyretics in a German Hospital. [europepmc]
- A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric Population. [europepmc]
- Review on Starter Pellets: Inert and Functional Cores. [europepmc]
- Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged ≥2-<7 Years: Results of an Open-Label Randomised Study. [europepmc]
- Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children. [europepmc]
- Stability of Oral Liquid Dosage Forms in Pediatric Cardiology: A Prerequisite for Patient's Safety-A Narrative Review. [europepmc]
- Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study. [europepmc]
Related